Literature DB >> 27733366

Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.

Mark R Hanudel1, Kristine Chua2, Maxime Rappaport3, Victoria Gabayan2, Erika Valore2, David Goltzman4, Tomas Ganz2, Elizabeta Nemeth2, Isidro B Salusky3.   

Abstract

In the setting of normal kidney function, iron deficiency is associated with increased FGF23 production and cleavage, altering circulating FGF23 levels. Our objective was to determine how chronic kidney disease (CKD) and dietary iron intake affect FGF23 production and metabolism in wild-type (WT) and hepcidin knockout (HKO) mice. For 8 wk, the mice were fed diets that contained adenine (to induce CKD) or no adenine (control group), with either low-iron (4 ppm) or standard-iron (335 ppm) concentrations. The low-iron diet induced iron deficiency anemia in both the WT and HKO mice. Among the WT mice, in both the control and CKD groups, a low-iron compared with a standard-iron diet increased bone Fgf23 mRNA expression, C-terminal FGF23 (cFGF23) levels, and FGF23 cleavage as manifested by a lower percentage intact FGF23 (iFGF23). Independent of iron status, CKD was associated with inhibition of FGF23 cleavage. Similar results were observed in the HKO control and CKD groups. Dietary iron content was more influential on FGF23 parameters than the presence or absence of hepcidin. In the CKD mice (WT and HKO, total n = 42), independent of the effects of serum phosphate, iron deficiency was associated with increased FGF23 production but also greater cleavage, whereas worse kidney function was associated with increased FGF23 production but decreased cleavage. Therefore, in both the WT and HKO mouse models, dietary iron content and CKD affected FGF23 production and metabolism.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  chronic kidney disease; fibroblast growth factor 23; hepcidin; iron deficiency anemia

Mesh:

Substances:

Year:  2016        PMID: 27733366      PMCID: PMC5210202          DOI: 10.1152/ajprenal.00281.2016

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Authors:  Erik A Imel; Munro Peacock; Amie K Gray; Leah R Padgett; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

3.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

4.  Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort.

Authors:  Bradley A Warady; Alison G Abraham; George J Schwartz; Craig S Wong; Alvaro Muñoz; Aisha Betoko; Mark Mitsnefes; Frederick Kaskel; Larry A Greenbaum; Robert H Mak; Joseph Flynn; Marva M Moxey-Mims; Susan Furth
Journal:  Am J Kidney Dis       Date:  2015-03-19       Impact factor: 8.860

5.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

6.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

7.  Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.

Authors:  Anupama Mohanram; Zhongxin Zhang; Shahnaz Shahinfar; William F Keane; Barry M Brenner; Robert D Toto
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

8.  Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.

Authors:  Erica L Clinkenbeard; Emily G Farrow; Lelia J Summers; Taryn A Cass; Jessica L Roberts; Christine A Bayt; Tim Lahm; Marjorie Albrecht; Matthew R Allen; Munro Peacock; Kenneth E White
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

9.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Authors:  Myles Wolf; Todd A Koch; David B Bregman
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more
  31 in total

1.  C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.

Authors:  Michele F Eisenga; Marco van Londen; David E Leaf; Ilja M Nolte; Gerjan Navis; Stephan J L Bakker; Martin H de Borst; Carlo A J M Gaillard
Journal:  J Am Soc Nephrol       Date:  2017-08-03       Impact factor: 10.121

2.  Acute blood loss stimulates fibroblast growth factor 23 production.

Authors:  Seham Rabadi; Ikemesit Udo; David E Leaf; Sushrut S Waikar; Marta Christov
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-06

3.  Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease.

Authors:  Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin
Journal:  Kidney Int       Date:  2020-06-20       Impact factor: 10.612

Review 4.  Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.

Authors:  Mark R Hanudel; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 5.  Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Authors:  Mark R Hanudel; Marciana Laster; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 6.  Intestinal calcium transport and its regulation in thalassemia: interaction between calcium and iron metabolism.

Authors:  Kornkamon Lertsuwan; Kannikar Wongdee; Jarinthorn Teerapornpuntakit; Narattaphol Charoenphandhu
Journal:  J Physiol Sci       Date:  2018-02-26       Impact factor: 2.781

7.  Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.

Authors:  Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz
Journal:  Nephrol Dial Transplant       Date:  2019-12-01       Impact factor: 5.992

8.  Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Authors:  Connor Francis; Guillaume Courbon; Claire Gerber; Samantha Neuburg; Xueyan Wang; Corey Dussold; Maralee Capella; Lixin Qi; Tamara Isakova; Rupal Mehta; Aline Martin; Myles Wolf; Valentin David
Journal:  Kidney Int       Date:  2019-08-30       Impact factor: 10.612

9.  Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets.

Authors:  C Liu; X Li; Z Zhao; Y Chi; L Cui; Q Zhang; F Ping; X Chai; Y Jiang; O Wang; M Li; X Xing; W Xia
Journal:  Osteoporos Int       Date:  2020-09-30       Impact factor: 4.507

10.  Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.

Authors:  Mark R Hanudel; Marciana Laster; Georgina Ramos; Barbara Gales; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2018-06-28       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.